DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Wednesday. The firm set a “hold” rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Price Performance

Shares of DBVT opened at $4.23 on Wednesday. The business has a 50-day moving average of $4.04 and a 200-day moving average of $3.83. The company has a market capitalization of $86.90 million, a price-to-earnings ratio of -0.94 and a beta of 0.67. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.09.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.